Identification

Name
Lornoxicam
Accession Number
DB06725
Type
Small Molecule
Groups
Approved, Investigational
Description

Lornoxicam (chlortenoxicam) is a new nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class with analgesic, anti-inflammatory and antipyretic properties. Lornoxicam differs from other oxicam compounds in its potent inhibition of prostaglandin biosynthesis, a property that explains the particularly pronounced efficacy of the drug. Lornoxicam is approved for use in Japan.

Structure
Thumb
Synonyms
  • Chlortenoxicam
  • Lornoxicamum
External IDs
CCRIS 8589 / Ro 13-9297
International/Other Brands
Lorcam (Taisho Pharmaceutical Co.) / Xafon (Nycomed)
Categories
UNII
ER09126G7A
CAS number
70374-39-9
Weight
Average: 371.81
Monoisotopic: 370.9801259
Chemical Formula
C13H10ClN3O4S2
InChI Key
WLHQHAUOOXYABV-UHFFFAOYSA-N
InChI
InChI=1S/C13H10ClN3O4S2/c1-17-10(13(19)16-9-4-2-3-5-15-9)11(18)12-7(23(17,20)21)6-8(14)22-12/h2-6,18H,1H3,(H,15,16,19)
IUPAC Name
6-chloro-4-hydroxy-2-methyl-1,1-dioxo-N-(pyridin-2-yl)-2H-1λ⁶-thieno[2,3-e][1,2]thiazine-3-carboxamide
SMILES
CN1C(C(=O)NC2=CC=CC=N2)=C(O)C2=C(C=C(Cl)S2)S1(=O)=O

Pharmacology

Indication

For the treatment of acute mild to moderate pain, as well as pain and inflammation of the joints caused by certain types of rheumatic diseases.

Pharmacodynamics

Lornoxicam is a non-steroidal anti-inflammatory drug (NSAID) that belongs to the oxicam class. As with other NSAIDS, lornoxicam is a potent inhibitor of the cyclooxgenase enzymes, which are responsible for catalyzing the formation of prostaglandins (act as messenger molecules in the process of inflammation) and thromboxane from arachidonic acid. Unlike some NSAIDS, lornoxicam's inhibition of cyclooxygenase does not lead to an increase in leukotriene formation, meaning that arachidonic acid is not moved to the 5-lipoxygenase cascade, resulting in the minimization of the risk of adverse events.

Mechanism of action

Like other NSAIDS, lornoxicam's anti-inflammatory and analgesic activity is related to its inhibitory action on prostaglandin and thromboxane synthesis through the inhibition of both COX-1 and COX-2. This leads to the reduction of inflammation, pain, fever, and swelling, which are mediated by prostaglandins. However, the exact mechanism of lornoxicam, like that of the other NSAIDs, has not been fully determined.

TargetActionsOrganism
AProstaglandin G/H synthase 1
inhibitor
Human
AProstaglandin G/H synthase 2
inhibitor
Human
Absorption

Lornoxicam is absorbed rapidly and almost completely from the GI tract (90-100%).

Volume of distribution
Not Available
Protein binding

Lornoxicam is 99% bound to plasma proteins (almost exlusively to serum albumin).

Metabolism

Lornoxicam is metabolized completely by cyp 2C9 with the principal metabolite being 5'-hydroxy-lornoxicam and only negligible amounts of intact lornoxicam are excreted unchanged in the urine. Approximately 2/3 of the drug is eliminated via the liver and 1/3 via the kidneys in the active form.

Route of elimination
Not Available
Half life

3-5 hours

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Lornoxicam Action PathwayDrug action
Lornoxicam Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Lornoxicam.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with 5-androstenedione.Experimental, Illicit
AbciximabLornoxicam may increase the anticoagulant activities of Abciximab.Approved
AbirateroneThe metabolism of Lornoxicam can be decreased when combined with Abiraterone.Approved
AcebutololLornoxicam may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolLornoxicam may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
Acetyl sulfisoxazoleThe metabolism of Lornoxicam can be decreased when combined with Acetyl sulfisoxazole.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Lornoxicam.Approved
AlaproclateAlaproclate may increase the antiplatelet activities of Lornoxicam.Experimental
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Lornoxicam.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Alendronic acid.Approved
AliskirenLornoxicam may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Lornoxicam.Experimental
AlprenololLornoxicam may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Lornoxicam.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Amcinonide.Approved
AmikacinThe risk or severity of nephrotoxicity can be increased when Lornoxicam is combined with Amikacin.Approved, Investigational, Vet Approved
AmilorideLornoxicam may decrease the antihypertensive activities of Amiloride.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Aminosalicylic Acid.Approved
AmlodipineThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Lornoxicam.Approved
AncrodLornoxicam may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Lornoxicam.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Lornoxicam is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Lornoxicam.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Lornoxicam.Approved, Investigational
Antithrombin III humanLornoxicam may increase the anticoagulant activities of Antithrombin III human.Approved
AntrafenineThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Antrafenine.Approved
ApalutamideThe serum concentration of Lornoxicam can be decreased when it is combined with Apalutamide.Approved, Investigational
ApixabanLornoxicam may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Lornoxicam.Investigational
ApramycinLornoxicam may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Lornoxicam.Approved, Investigational
AprepitantThe metabolism of Lornoxicam can be increased when combined with Aprepitant.Approved, Investigational
ArbekacinLornoxicam may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinLornoxicam may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanLornoxicam may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololLornoxicam may decrease the antihypertensive activities of Arotinolol.Investigational
AsenapineLornoxicam may decrease the antihypertensive activities of Asenapine.Approved
AtamestaneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Atamestane.Investigational
AtenololLornoxicam may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Lornoxicam.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Lornoxicam.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Lornoxicam.Approved, Investigational
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Lornoxicam.Investigational
BacitracinThe risk or severity of nephrotoxicity can be increased when Lornoxicam is combined with Bacitracin.Approved, Vet Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Lornoxicam.Approved, Investigational
BazedoxifeneLornoxicam may increase the thrombogenic activities of Bazedoxifene.Approved, Investigational
BecaplerminLornoxicam may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of gastrointestinal irritation can be increased when Beclomethasone dipropionate is combined with Lornoxicam.Approved, Investigational
BefunololLornoxicam may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinLornoxicam may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Lornoxicam.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Lornoxicam.Approved
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Lornoxicam.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Lornoxicam.Withdrawn
BenzthiazideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Lornoxicam.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Lornoxicam.Approved
BepridilThe therapeutic efficacy of Bepridil can be decreased when used in combination with Lornoxicam.Approved, Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Lornoxicam.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Betamethasone.Approved, Vet Approved
BetaxololLornoxicam may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Lornoxicam.Approved, Investigational
BevantololLornoxicam may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Lornoxicam.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Lornoxicam.Approved, Investigational
BisoprololLornoxicam may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinLornoxicam may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololLornoxicam may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Lornoxicam.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Lornoxicam.Investigational
BucindololLornoxicam may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Lornoxicam.Approved
BufexamacThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Bufexamac.Approved, Experimental
BufuralolLornoxicam may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Lornoxicam.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Lornoxicam.Approved
BupranololLornoxicam may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Lornoxicam.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Lornoxicam.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Candoxatril.Experimental
CapecitabineThe metabolism of Lornoxicam can be decreased when combined with Capecitabine.Approved, Investigational
CapsaicinThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Capsaicin.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Captopril.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Lornoxicam.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Lornoxicam.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Lornoxicam.Approved, Vet Approved, Withdrawn
CarteololLornoxicam may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolLornoxicam may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Lornoxicam.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Lornoxicam.Approved, Investigational
CeliprololLornoxicam may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Lornoxicam can be increased when it is combined with Ceritinib.Approved
CertoparinLornoxicam may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Lornoxicam.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Lornoxicam.Approved, Vet Approved
ChlorotrianiseneLornoxicam may increase the thrombogenic activities of Chlorotrianisene.Investigational, Withdrawn
ChlorphenesinThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Lornoxicam.Approved
CholecalciferolThe metabolism of Lornoxicam can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholestyramineCholestyramine can cause a decrease in the absorption of Lornoxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Lornoxicam.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Cilazapril.Approved
CimicoxibThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Cimicoxib.Investigational
CinoxacinLornoxicam may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinLornoxicam may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
CisplatinThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Cisplatin.Approved
CitalopramCitalopram may increase the antiplatelet activities of Lornoxicam.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Lornoxicam.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Lornoxicam.Vet Approved
CloranololLornoxicam may decrease the antihypertensive activities of Cloranolol.Experimental
ClorindioneLornoxicam may increase the anticoagulant activities of Clorindione.Experimental
ColesevelamColesevelam can cause a decrease in the absorption of Lornoxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Lornoxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Conjugated estrogensLornoxicam may increase the thrombogenic activities of Conjugated estrogens.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Cortisone acetate.Approved, Investigational
CrisaboroleThe metabolism of Lornoxicam can be decreased when combined with Crisaborole.Approved, Investigational
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Lornoxicam.Approved, Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Lornoxicam.Experimental
CyclosporineThe risk or severity of renal failure and hypertension can be increased when Lornoxicam is combined with Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateLornoxicam may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Lornoxicam can be decreased when it is combined with Dabrafenib.Approved, Investigational
DaidzeinLornoxicam may increase the thrombogenic activities of Daidzein.Experimental
DalteparinLornoxicam may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidLornoxicam may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapoxetineDapoxetine may increase the antiplatelet activities of Lornoxicam.Investigational
DarexabanLornoxicam may increase the anticoagulant activities of Darexaban.Investigational
DeferasiroxThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Delapril.Investigational
DelavirdineThe metabolism of Lornoxicam can be decreased when combined with Delavirdine.Approved
DesipramineLornoxicam may decrease the antihypertensive activities of Desipramine.Approved, Investigational
DesirudinLornoxicam may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DesvenlafaxineDesvenlafaxine may increase the antiplatelet activities of Lornoxicam.Approved, Investigational
DexamethasoneThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Lornoxicam.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Dexamethasone isonicotinate.Vet Approved
DexibuprofenThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Dexibuprofen.Approved, Investigational
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Lornoxicam.Approved, Investigational
DexniguldipineThe therapeutic efficacy of Dexniguldipine can be decreased when used in combination with Lornoxicam.Experimental
DextranLornoxicam may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DibekacinLornoxicam may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
Dibotermin alfaThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Dibotermin alfa.Approved, Investigational
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Lornoxicam.Approved, Vet Approved
DicoumarolLornoxicam may increase the anticoagulant activities of Dicoumarol.Approved
DienestrolLornoxicam may increase the thrombogenic activities of Dienestrol.Approved, Investigational
DiethylstilbestrolLornoxicam may increase the thrombogenic activities of Diethylstilbestrol.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Lornoxicam.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Lornoxicam.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Lornoxicam.Approved
DihydrostreptomycinLornoxicam may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DiltiazemThe therapeutic efficacy of Diltiazem can be decreased when used in combination with Lornoxicam.Approved, Investigational
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Lornoxicam.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Lornoxicam.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Lornoxicam.Approved
DiphenadioneLornoxicam may increase the anticoagulant activities of Diphenadione.Experimental
DosulepinThe metabolism of Lornoxicam can be decreased when combined with Dosulepin.Approved
DoxazosinThe therapeutic efficacy of Doxazosin can be decreased when used in combination with Lornoxicam.Approved
DrospirenoneLornoxicam may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Droxicam.Withdrawn
DuloxetineDuloxetine may increase the antiplatelet activities of Lornoxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Lornoxicam.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Lornoxicam.Investigational
Edetic AcidLornoxicam may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanLornoxicam may increase the anticoagulant activities of Edoxaban.Approved
EfavirenzThe metabolism of Lornoxicam can be decreased when combined with Efavirenz.Approved, Investigational
EfonidipineThe therapeutic efficacy of Efonidipine can be decreased when used in combination with Lornoxicam.Approved, Investigational
EnalaprilThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Enalaprilat.Approved
EnoxacinLornoxicam may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinLornoxicam may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Lornoxicam.Experimental
EpanololLornoxicam may decrease the antihypertensive activities of Epanolol.Experimental
EpimestrolLornoxicam may increase the thrombogenic activities of Epimestrol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Lornoxicam.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Lornoxicam.Experimental
EplerenoneLornoxicam may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Lornoxicam.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Lornoxicam.Approved
EquileninThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Equilin.Approved
EquolLornoxicam may increase the thrombogenic activities of Equol.Investigational
EsatenololLornoxicam may decrease the antihypertensive activities of Esatenolol.Experimental
EscitalopramEscitalopram may increase the antiplatelet activities of Lornoxicam.Approved, Investigational
EsmololLornoxicam may decrease the antihypertensive activities of Esmolol.Approved
Estradiol acetateLornoxicam may increase the thrombogenic activities of Estradiol acetate.Approved, Investigational, Vet Approved
Estradiol cypionateLornoxicam may increase the thrombogenic activities of Estradiol cypionate.Approved, Investigational, Vet Approved
Estradiol valerateLornoxicam may increase the thrombogenic activities of Estradiol valerate.Approved, Investigational, Vet Approved
EstriolLornoxicam may increase the thrombogenic activities of Estriol.Approved, Investigational, Vet Approved
Estrogens, esterifiedLornoxicam may increase the thrombogenic activities of Estrogens, esterified.Approved
EstroneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Lornoxicam.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Lornoxicam.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Lornoxicam.Experimental
Ethyl biscoumacetateLornoxicam may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Lornoxicam.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Lornoxicam.Approved, Investigational
EtoperidoneEtoperidone may increase the antiplatelet activities of Lornoxicam.Withdrawn
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Lornoxicam.Approved, Investigational
EtravirineThe metabolism of Lornoxicam can be decreased when combined with Etravirine.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Lornoxicam.Investigational, Nutraceutical
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Lornoxicam.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Lornoxicam.Experimental
FelodipineThe therapeutic efficacy of Felodipine can be decreased when used in combination with Lornoxicam.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Lornoxicam.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Lornoxicam.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Lornoxicam.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Lornoxicam.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Lornoxicam.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Lornoxicam.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Lornoxicam.Approved, Investigational
FleroxacinLornoxicam may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Lornoxicam.Approved, Withdrawn
FloxuridineThe metabolism of Lornoxicam can be decreased when combined with Floxuridine.Approved
FluasteroneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Fluasterone.Investigational
FluconazoleThe metabolism of Lornoxicam can be decreased when combined with Fluconazole.Approved, Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Fludrocortisone.Approved, Investigational
FluindioneLornoxicam may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequineLornoxicam may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Lornoxicam.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Lornoxicam.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Fluorometholone.Approved, Investigational
FluorouracilThe metabolism of Lornoxicam can be decreased when combined with Fluorouracil.Approved
FluoxetineFluoxetine may increase the antiplatelet activities of Lornoxicam.Approved, Vet Approved
FluprednideneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Lornoxicam.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Lornoxicam.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of gastrointestinal irritation can be increased when Fluticasone propionate is combined with Lornoxicam.Approved
FluvoxamineFluvoxamine may increase the antiplatelet activities of Lornoxicam.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Lornoxicam.Approved, Nutraceutical, Vet Approved
FondaparinuxLornoxicam may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Lornoxicam.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Lornoxicam is combined with Fosinopril.Approved
FosphenytoinThe metabolism of Lornoxicam can be increased when combined with Fosphenytoin.Approved, Investigational
FramycetinLornoxicam may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Lornoxicam.Approved, Vet Approved
GabexateLornoxicam may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinLornoxicam may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinLornoxicam may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Lornoxicam.Approved, Withdrawn
GemfibrozilThe metabolism of Lornoxicam can be decreased when combined with Gemfibrozil.Approved
GemifloxacinLornoxicam may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinLornoxicam may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GenisteinLornoxicam may increase the thrombogenic activities of Genistein.Investigational
GentamicinLornoxicam may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ALornoxicam may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GinsengThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Ginseng.Approved, Investigational, Nutraceutical
GlipizideThe protein binding of Glipizide can be decreased when combined with Lornoxicam.Approved, Investigational
GlyburideThe protein binding of Glyburide can be decreased when combined with Lornoxicam.Approved
GrepafloxacinLornoxicam may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Lornoxicam.Experimental
GuanfacineThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Lornoxicam.Approved, Investigational
HalcinonideThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Lornoxicam is combined with HE3286.Investigational
HeparinLornoxicam may increase the anticoagulant activities of Heparin.Approved, Investigational
HexestrolLornoxicam may increase the thrombogenic activities of Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Lornoxicam.Investigational
HydralazineLornoxicam may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Lornoxicam.Approved, Vet Approved
HydrocortisoneThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Lornoxicam.Approved, Vet Approved
Hydrocortisone acetateThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone acetate is combined with Lornoxicam.Approved, Vet Approved
Hydrocortisone butyrateThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone butyrate is combined with Lornoxicam.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Lornoxicam.Approved, Investigational
Hygromycin BLornoxicam may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of gastrointestinal bleeding can be increased when Lornoxicam is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Lornoxicam.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Lornoxicam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Lornoxicam.Approved, Investigational
IcosapentThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Icosapent.Approved, Nutraceutical
IdraparinuxLornoxicam may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Lornoxicam.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Lornoxicam.Experimental
IndalpineIndalpine may increase the antiplatelet activities of Lornoxicam.Investigational, Withdrawn
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Lornoxicam.Approved
IndenololLornoxicam may decrease the antihypertensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Lornoxicam can be decreased when combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Lornoxicam.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Lornoxicam.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Lornoxicam.Withdrawn
IrbesartanThe metabolism of Lornoxicam can be decreased when combined with Irbesartan.Approved, Investigational
IsepamicinLornoxicam may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Lornoxicam.Withdrawn
IsradipineThe therapeutic efficacy of Isradipine can be decreased when used in combination with Lornoxicam.Approved, Investigational
IstaroximeThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Istaroxime.Investigational
KanamycinLornoxicam may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Lornoxicam.Experimental
KetoconazoleThe metabolism of Lornoxicam can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Lornoxicam.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Lornoxicam.Approved
LabetalolLornoxicam may decrease the antihypertensive activities of Labetalol.Approved
LacidipineThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Lornoxicam.Approved, Investigational
LandiololLornoxicam may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Lornoxicam.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Lornoxicam.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Lornoxicam.Approved, Investigational
LepirudinLornoxicam may increase the anticoagulant activities of Lepirudin.Approved
LercanidipineThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Lornoxicam.Approved, Investigational
LetaxabanLornoxicam may increase the anticoagulant activities of Letaxaban.Investigational
LevobetaxololLornoxicam may decrease the antihypertensive activities of Levobetaxolol.Approved, Investigational
LevobunololLornoxicam may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinLornoxicam may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the antiplatelet activities of Lornoxicam.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Lornoxicam.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Lornoxicam.Investigational
Lithium cationThe serum concentration of Lithium can be increased when it is combined with Lornoxicam.Experimental
LobeglitazoneThe metabolism of Lornoxicam can be decreased when combined with Lobeglitazone.Approved, Investigational
LomefloxacinLornoxicam may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Lornoxicam.Experimental
LosartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Lornoxicam.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Loteprednol.Approved
LovastatinThe metabolism of Lornoxicam can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Lornoxicam.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Lornoxicam.Approved, Investigational
LumacaftorThe serum concentration of Lornoxicam can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Lornoxicam.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Lornoxicam.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Lornoxicam.Approved
ManidipineThe therapeutic efficacy of Manidipine can be decreased when used in combination with Lornoxicam.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Lornoxicam.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Lornoxicam is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Lornoxicam.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Lornoxicam.Approved
MelagatranLornoxicam may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Lornoxicam.Approved, Vet Approved
MepindololLornoxicam may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Lornoxicam.Approved
MestranolLornoxicam may increase the thrombogenic activities of Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Lornoxicam.Approved, Investigational, Withdrawn
MethallenestrilLornoxicam may increase the thrombogenic activities of Methallenestril.Experimental
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Lornoxicam.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Lornoxicam.Approved
Methyl salicylateThe therapeutic efficacy of Methyl salicylate can be decreased when used in combination with Lornoxicam.Approved, Vet Approved
MethylprednisoloneThe risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Lornoxicam.Approved, Vet Approved
MetipranololLornoxicam may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Lornoxicam.Approved
MetoprololLornoxicam may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MibefradilThe therapeutic efficacy of Mibefradil can be decreased when used in combination with Lornoxicam.Investigational, Withdrawn
MicronomicinLornoxicam may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MidostaurinThe metabolism of Lornoxicam can be decreased when combined with Midostaurin.Approved, Investigational
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Lornoxicam.Approved, Experimental
MifepristoneThe serum concentration of Lornoxicam can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranMilnacipran may increase the antiplatelet activities of Lornoxicam.Approved, Investigational
MinoxidilThe therapeutic efficacy of Minoxidil can be decreased when used in combination with Lornoxicam.Approved, Investigational
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Lornoxicam.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Lornoxicam.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Lornoxicam.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Lornoxicam.Approved
MoxestrolLornoxicam may increase the thrombogenic activities of Moxestrol.Experimental
MoxifloxacinLornoxicam may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Lornoxicam.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Lornoxicam.Approved
NabiloneThe metabolism of Lornoxicam can be decreased when combined with Nabilone.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Lornoxicam.Approved
NadololLornoxicam may decrease the antihypertensive activities of Nadolol.Approved
NadroparinLornoxicam may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Lornoxicam.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Lornoxicam.Approved
NaftopidilThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Lornoxicam.Investigational
Nalidixic AcidLornoxicam may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Lornoxicam.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Lornoxicam is combined with NCX 1022.Investigational
NeamineLornoxicam may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololLornoxicam may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NefazodoneNefazodone may increase the antiplatelet activities of Lornoxicam.Approved, Withdrawn
NemonoxacinLornoxicam may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinThe risk or severity of nephrotoxicity can be increased when Lornoxicam is combined with Neomycin.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Lornoxicam.Approved, Investigational
NetilmicinLornoxicam may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NicardipineThe therapeutic efficacy of Nicardipine can be decreased when used in combination with Lornoxicam.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Lornoxicam.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Lornoxicam.Approved
NiguldipineThe therapeutic efficacy of Niguldipine can be decreased when used in combination with Lornoxicam.Experimental
NilvadipineThe therapeutic efficacy of Nilvadipine can be decreased when used in combination with Lornoxicam.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Lornoxicam.Approved, Investigational, Withdrawn
NimodipineThe therapeutic efficacy of Nimodipine can be decreased when used in combination with Lornoxicam.Approved, Investigational
NisoldipineThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Lornoxicam.Approved
NitrendipineThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Lornoxicam.Approved, Investigational
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Lornoxicam.Investigational
NorfloxacinLornoxicam may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinLornoxicam may increase the neuroexcitatory activities of Ofloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Lornoxicam.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Lornoxicam.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Lornoxicam.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Lornoxicam is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Omapatrilat.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Lornoxicam.Vet Approved
OtamixabanLornoxicam may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Lornoxicam.Approved
Oxolinic acidLornoxicam may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololLornoxicam may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Lornoxicam.Approved, Withdrawn
PalmidrolThe risk or severity of adverse effects can be increased when Palmidrol is combined with Lornoxicam.Experimental, Nutraceutical
PamidronateThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Parecoxib.Approved
ParomomycinThe risk or severity of nephrotoxicity can be increased when Lornoxicam is combined with Paromomycin.Approved, Investigational
ParoxetineParoxetine may increase the antiplatelet activities of Lornoxicam.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Lornoxicam.Approved, Investigational
PazufloxacinLornoxicam may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinLornoxicam may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololLornoxicam may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateLornoxicam may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateLornoxicam may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Perindopril.Approved
PhenindioneLornoxicam may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonLornoxicam may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Lornoxicam.Approved, Vet Approved
PhenytoinThe metabolism of Lornoxicam can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Lornoxicam.Approved, Investigational
PindololLornoxicam may decrease the antihypertensive activities of Pindolol.Approved, Investigational
Pipemidic acidLornoxicam may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Lornoxicam.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Lornoxicam.Approved, Investigational
Piromidic acidLornoxicam may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Lornoxicam.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Lornoxicam.Experimental
PitolisantThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Pitolisant.Approved, Investigational
Platelet Activating FactorLornoxicam may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinLornoxicam may decrease the excretion rate of Plazomicin which could result in a higher serum level.Approved, Investigational
Polyestradiol phosphateLornoxicam may increase the thrombogenic activities of Polyestradiol phosphate.Approved
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Lornoxicam.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Pomalidomide.Approved
Potassium CitrateLornoxicam may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
PractololLornoxicam may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Lornoxicam.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Lornoxicam.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Lornoxicam.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Pregnenolone.Approved, Experimental, Investigational
PrimidoneThe metabolism of Lornoxicam can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Lornoxicam can be increased when it is combined with Probenecid.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Lornoxicam.Experimental
PromestrieneLornoxicam may increase the thrombogenic activities of Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Lornoxicam.Approved, Investigational
PropafenoneLornoxicam may decrease the antihypertensive activities of Propafenone.Approved
PropranololLornoxicam may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Lornoxicam.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Lornoxicam.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Lornoxicam.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Lornoxicam.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Lornoxicam.Vet Approved
Protein CLornoxicam may increase the anticoagulant activities of Protein C.Approved
Protein S humanLornoxicam may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeLornoxicam may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinLornoxicam may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Lornoxicam.Investigational
PuromycinLornoxicam may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
PyrimethamineThe metabolism of Lornoxicam can be decreased when combined with Pyrimethamine.Approved, Investigational, Vet Approved
QuinaprilThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Quinapril.Approved, Investigational
QuinestrolLornoxicam may increase the thrombogenic activities of Quinestrol.Approved
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Lornoxicam.Approved
QuinineThe metabolism of Lornoxicam can be decreased when combined with Quinine.Approved
RamiprilThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Ramipril.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Lornoxicam.Approved, Experimental, Investigational
ReviparinLornoxicam may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinLornoxicam may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RifapentineThe metabolism of Lornoxicam can be increased when combined with Rifapentine.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Risedronate.Approved, Investigational
RivaroxabanLornoxicam may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Lornoxicam.Approved, Investigational, Withdrawn
RosoxacinLornoxicam may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RucaparibThe metabolism of Lornoxicam can be decreased when combined with Rucaparib.Approved, Investigational
RufloxacinLornoxicam may increase the neuroexcitatory activities of Rufloxacin.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Lornoxicam.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Lornoxicam.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Lornoxicam.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Lornoxicam.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Lornoxicam.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Lornoxicam.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Lornoxicam.Approved, Investigational
SecobarbitalThe metabolism of Lornoxicam can be increased when combined with Secobarbital.Approved, Vet Approved
SecoisolariciresinolLornoxicam may increase the thrombogenic activities of Secoisolariciresinol.Investigational
SeliciclibThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Seliciclib.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Lornoxicam.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Lornoxicam.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Lornoxicam.Investigational
SertralineSertraline may increase the antiplatelet activities of Lornoxicam.Approved
SildenafilThe metabolism of Lornoxicam can be decreased when combined with Sildenafil.Approved, Investigational
SisomicinLornoxicam may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinLornoxicam may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium CitrateThe risk or severity of bleeding and hemorrhage can be increased when Lornoxicam is combined with Sodium Citrate.Approved, Investigational
Sodium phosphate, monobasicThe risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Lornoxicam.Approved
SorafenibThe metabolism of Lornoxicam can be decreased when combined with Sorafenib.Approved, Investigational
SotalolLornoxicam may decrease the antihypertensive activities of Sotalol.Approved
SparfloxacinLornoxicam may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpiraprilThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Spirapril.Approved
SpironolactoneThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Lornoxicam is combined with Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Lornoxicam.Investigational
StreptomycinLornoxicam may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
SulfadiazineThe metabolism of Lornoxicam can be decreased when combined with Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleThe metabolism of Lornoxicam can be decreased when combined with Sulfamethoxazole.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Lornoxicam.Approved
SulfisoxazoleThe metabolism of Lornoxicam can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Lornoxicam.Approved, Investigational
SulodexideLornoxicam may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Lornoxicam.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Lornoxicam.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Lornoxicam.Experimental
Synthetic Conjugated Estrogens, ALornoxicam may increase the thrombogenic activities of Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BLornoxicam may increase the thrombogenic activities of Synthetic Conjugated Estrogens, B.Approved
TacrolimusLornoxicam may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Lornoxicam.Approved
TalinololLornoxicam may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Lornoxicam.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Lornoxicam.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Lornoxicam.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Lornoxicam.Approved, Investigational
TemafloxacinLornoxicam may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Temocapril.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Lornoxicam.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Lornoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Lornoxicam.Vet Approved
TerbutalineLornoxicam may decrease the antihypertensive activities of Terbutaline.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Lornoxicam.Approved
TertatololLornoxicam may decrease the antihypertensive activities of Tertatolol.Experimental
TetrahydropalmatineThe therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Lornoxicam.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Lornoxicam.Approved
TiboloneLornoxicam may increase the thrombogenic activities of Tibolone.Approved, Investigational
TicagrelorThe metabolism of Lornoxicam can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Lornoxicam can be decreased when combined with Ticlopidine.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololLornoxicam may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Lornoxicam.Investigational
TioclomarolLornoxicam may increase the anticoagulant activities of Tioclomarol.Experimental
TixocortolThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Tixocortol.Approved, Withdrawn
TobramycinLornoxicam may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TolbutamideThe metabolism of Lornoxicam can be decreased when combined with Tolbutamide.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Tolfenamic Acid.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Lornoxicam.Approved
TopiroxostatThe metabolism of Lornoxicam can be decreased when combined with Topiroxostat.Approved, Investigational
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Lornoxicam.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Trandolapril.Approved
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Lornoxicam.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Lornoxicam.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Triamcinolone.Approved, Vet Approved
TriamtereneLornoxicam may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Lornoxicam.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Lornoxicam.Approved, Vet Approved
TrimethoprimThe metabolism of Lornoxicam can be decreased when combined with Trimethoprim.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Lornoxicam.Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Trolamine salicylate.Approved
TrovafloxacinLornoxicam may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinLornoxicam may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Lornoxicam.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Lornoxicam.Approved, Investigational, Withdrawn
ValsartanThe metabolism of Lornoxicam can be decreased when combined with Valsartan.Approved, Investigational
VancomycinLornoxicam may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved
VenlafaxineVenlafaxine may increase the antiplatelet activities of Lornoxicam.Approved
VoriconazoleThe metabolism of Lornoxicam can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinLornoxicam may increase the anticoagulant activities of Warfarin.Approved
XimelagatranLornoxicam may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZafirlukastThe metabolism of Lornoxicam can be decreased when combined with Zafirlukast.Approved, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Lornoxicam.Approved, Investigational
ZeranolLornoxicam may increase the thrombogenic activities of Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Lornoxicam.Approved, Investigational, Withdrawn
ZimelidineZimelidine may increase the antiplatelet activities of Lornoxicam.Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Zofenopril.Experimental
Zoledronic acidThe risk or severity of gastrointestinal bleeding can be increased when Lornoxicam is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Lornoxicam.Withdrawn
Food Interactions
Not Available

References

General References
  1. Balfour JA, Fitton A, Barradell LB: Lornoxicam. A review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions. Drugs. 1996 Apr;51(4):639-57. [PubMed:8706598]
  2. Vane JR: Introduction: mechanism of action of NSAIDs. Br J Rheumatol. 1996 Apr;35 Suppl 1:1-3. [PubMed:8630629]
  3. Radhofer-Welte S, Rabasseda X: Lornoxicam, a new potent NSAID with an improved tolerability profile. Drugs Today (Barc). 2000 Jan;36(1):55-76. [PubMed:12879104]
  4. Skjodt NM, Davies NM: Clinical pharmacokinetics of lornoxicam. A short half-life oxicam. Clin Pharmacokinet. 1998 Jun;34(6):421-8. [PubMed:9646006]
  5. Olkkola KT, Brunetto AV, Mattila MJ: Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. Clin Pharmacokinet. 1994 Feb;26(2):107-20. [PubMed:8162655]
  6. Hitzenberger G, Radhofer-Welte S, Takacs F, Rosenow D: Pharmacokinetics of lornoxicam in man. Postgrad Med J. 1990;66 Suppl 4:S22-7. [PubMed:2284217]
  7. Pruss TP, Stroissnig H, Radhofer-Welte S, Wendtlandt W, Mehdi N, Takacs F, Fellier H: Overview of the pharmacological properties, pharmacokinetics and animal safety assessment of lornoxicam. Postgrad Med J. 1990;66 Suppl 4:S18-21. [PubMed:2284216]
  8. Bonnabry P, Leemann T, Dayer P: Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam. Eur J Clin Pharmacol. 1996;49(4):305-8. [PubMed:8857077]
External Links
KEGG Drug
D01866
PubChem Compound
54690031
PubChem Substance
99443271
ChemSpider
10442760
BindingDB
92331
ChEBI
31783
ChEMBL
CHEMBL1569487
PharmGKB
PA165958395
Wikipedia
Lornoxicam
ATC Codes
M01AC05 — Lornoxicam

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedPreventionPost Operative Endodontic Pain1
2CompletedTreatmentBunionectomy / Orthopedic Procedures1
2CompletedTreatmentHeadache (Migraine)1
2TerminatedTreatmentAlzheimer's Disease (AD)1
3CompletedTreatmentPostoperative pain1
3Unknown StatusPreventionInguinal Hernias / Postoperative pain1
4CompletedTreatmentAcute Coronary Syndromes (ACS)1
4CompletedTreatmentPostoperative pain1
4RecruitingTreatmentBacillus Calmette-Guerin (BCG) Cystitis / Intra-vesical Instillation / Non-Muscle-invasive Bladder Cancer (NMIBC)1
Not AvailableCompletedTreatmentKnee Osteoarthritis (Knee OA)1
Not AvailableCompletedTreatmentOsteoarthritis of the Knee Joint1
Not AvailableUnknown StatusTreatmentPain1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP2.62BIOBYTE STARLIST (2009)
Predicted Properties
PropertyValueSource
Water Solubility0.0437 mg/mLALOGPS
logP3.08ALOGPS
logP0.64ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)1.82ChemAxon
pKa (Strongest Basic)4.22ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area99.6 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity87.9 m3·mol-1ChemAxon
Polarizability33.3 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9964
Blood Brain Barrier-0.964
Caco-2 permeable+0.7528
P-glycoprotein substrateSubstrate0.5511
P-glycoprotein inhibitor INon-inhibitor0.8209
P-glycoprotein inhibitor IINon-inhibitor0.8506
Renal organic cation transporterNon-inhibitor0.9132
CYP450 2C9 substrateSubstrate0.6831
CYP450 2D6 substrateNon-substrate0.8868
CYP450 3A4 substrateNon-substrate0.6652
CYP450 1A2 substrateNon-inhibitor0.7958
CYP450 2C9 inhibitorInhibitor0.7138
CYP450 2D6 inhibitorNon-inhibitor0.8714
CYP450 2C19 inhibitorNon-inhibitor0.7777
CYP450 3A4 inhibitorNon-inhibitor0.8755
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7815
Ames testNon AMES toxic0.8009
CarcinogenicityNon-carcinogens0.6844
BiodegradationNot ready biodegradable0.9851
Rat acute toxicity3.8570 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9494
hERG inhibition (predictor II)Non-inhibitor0.8681
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00di-2619000000-b00c34491f32edc2be89
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00di-4920000000-9f82e448f745973a1607

Taxonomy

Description
This compound belongs to the class of organic compounds known as alpha amino acids and derivatives. These are amino acids in which the amino group is attached to the carbon atom immediately adjacent to the carboxylate group (alpha carbon), or a derivative thereof.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Alpha amino acids and derivatives
Alternative Parents
Thienothiazines / 2,3,5-trisubstituted thiophenes / N-arylamides / 1,2-thiazines / Aryl chlorides / Imidolactams / Organosulfonamides / Pyridines and derivatives / Vinylogous acids / Heteroaromatic compounds
show 7 more
Substituents
Alpha-amino acid or derivatives / Thienothiazine / N-arylamide / 2,3,5-trisubstituted thiophene / Ortho-thiazine / Aryl chloride / Aryl halide / Organosulfonic acid amide / Pyridine / Imidolactam
show 20 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
monocarboxylic acid amide, organochlorine compound, pyridines, heteroaryl hydroxy compound, thienothiazine (CHEBI:31783)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Renner RM, Jensen JT, Nichols MD, Edelman AB: Pain control in first-trimester surgical abortion: a systematic review of randomized controlled trials. Contraception. 2010 May;81(5):372-88. doi: 10.1016/j.contraception.2009.12.008. Epub 2010 Jan 27. [PubMed:20399943]
  2. Berg J, Fellier H, Christoph T, Grarup J, Stimmeder D: The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro. Inflamm Res. 1999 Jul;48(7):369-79. [PubMed:10450786]
  3. Rose P, Steinhauser C: Comparison of Lornoxicam and Rofecoxib in Patients with Activated Osteoarthritis (COLOR Study). Clin Drug Investig. 2004;24(4):227-36. [PubMed:17516707]
  4. Bianchi M, Panerai AE: Effects of lornoxicam, piroxicam, and meloxicam in a model of thermal hindpaw hyperalgesia induced by formalin injection in rat tail. Pharmacol Res. 2002 Feb;45(2):101-5. [PubMed:11846620]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Renner RM, Jensen JT, Nichols MD, Edelman AB: Pain control in first-trimester surgical abortion: a systematic review of randomized controlled trials. Contraception. 2010 May;81(5):372-88. doi: 10.1016/j.contraception.2009.12.008. Epub 2010 Jan 27. [PubMed:20399943]
  2. Berg J, Fellier H, Christoph T, Grarup J, Stimmeder D: The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro. Inflamm Res. 1999 Jul;48(7):369-79. [PubMed:10450786]
  3. Rose P, Steinhauser C: Comparison of Lornoxicam and Rofecoxib in Patients with Activated Osteoarthritis (COLOR Study). Clin Drug Investig. 2004;24(4):227-36. [PubMed:17516707]
  4. Bianchi M, Panerai AE: Effects of lornoxicam, piroxicam, and meloxicam in a model of thermal hindpaw hyperalgesia induced by formalin injection in rat tail. Pharmacol Res. 2002 Feb;45(2):101-5. [PubMed:11846620]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Rodrigues AD: Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same? Drug Metab Dispos. 2005 Nov;33(11):1567-75. Epub 2005 Aug 23. [PubMed:16118328]
  2. Martinez C, Blanco G, Garcia-Martin E, Agundez JA: [Clinical pharmacogenomics for CYP2C8 and CYP2C9: general concepts and application to the use of NSAIDs]. Farm Hosp. 2006 Jul-Aug;30(4):240-8. [PubMed:17022718]
  3. Zhang Y, Zhong D, Si D, Guo Y, Chen X, Zhou H: Lornoxicam pharmacokinetics in relation to cytochrome P450 2C9 genotype. Br J Clin Pharmacol. 2005 Jan;59(1):14-7. [PubMed:15606435]
  4. Kohl C, Steinkellner M: Prediction of pharmacokinetic drug/drug interactions from In vitro data: interactions of the nonsteroidal anti-inflammatory drug lornoxicam with oral anticoagulants. Drug Metab Dispos. 2000 Feb;28(2):161-8. [PubMed:10640513]
  5. Bonnabry P, Leemann T, Dayer P: Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam. Eur J Clin Pharmacol. 1996;49(4):305-8. [PubMed:8857077]
  6. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  7. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  8. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Drug created on August 18, 2010 12:12 / Updated on August 02, 2018 05:39